Cargando…
Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study
AIMS/HYPOTHESIS: Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metfor...
Autores principales: | , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477943/ https://www.ncbi.nlm.nih.gov/pubmed/35902387 http://dx.doi.org/10.1007/s00125-022-05743-0 |
_version_ | 1784790473056976896 |
---|---|
author | Zheng, Jie Xu, Min Walker, Venexia Yuan, Jinqiu Korologou-Linden, Roxanna Robinson, Jamie Huang, Peiyuan Burgess, Stephen Au Yeung, Shiu Lun Luo, Shan Holmes, Michael V. Davey Smith, George Ning, Guang Wang, Weiqing Gaunt, Tom R. Bi, Yufang |
author_facet | Zheng, Jie Xu, Min Walker, Venexia Yuan, Jinqiu Korologou-Linden, Roxanna Robinson, Jamie Huang, Peiyuan Burgess, Stephen Au Yeung, Shiu Lun Luo, Shan Holmes, Michael V. Davey Smith, George Ning, Guang Wang, Weiqing Gaunt, Tom R. Bi, Yufang |
author_sort | Zheng, Jie |
collection | PubMed |
description | AIMS/HYPOTHESIS: Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metformin targets on Alzheimer’s disease and potential causal mechanisms in the brain linking the two. METHODS: Genetic proxies for the effects of metformin drug targets were identified as variants in the gene for the corresponding target that associated with HbA(1c) level (N=344,182) and expression level of the corresponding gene (N≤31,684). The cognitive outcomes were derived from genome-wide association studies comprising 527,138 middle-aged Europeans, including 71,880 with Alzheimer’s disease or Alzheimer’s disease-by-proxy. MR estimates representing lifelong metformin use on Alzheimer’s disease and cognitive function in the general population were generated. Effect of expression level of 22 metformin-related genes in brain cortex (N=6601 donors) on Alzheimer’s disease was further estimated. RESULTS: Genetically proxied metformin use, equivalent to a 6.75 mmol/mol (1.09%) reduction on HbA(1c), was associated with 4% lower odds of Alzheimer’s disease (OR 0.96 [95% CI 0.95, 0.98], p=1.06×10(−4)) in non-diabetic individuals. One metformin target, mitochondrial complex 1 (MCI), showed a robust effect on Alzheimer’s disease (OR 0.88, p=4.73×10(−4)) that was independent of AMP-activated protein kinase. MR of expression in brain cortex tissue showed that decreased MCI-related gene (NDUFA2) expression was associated with lower Alzheimer’s disease risk (OR 0.95, p=4.64×10(−4)) and favourable cognitive function. CONCLUSIONS/INTERPRETATION: Metformin use may cause reduced Alzheimer’s disease risk in the general population. Mitochondrial function and the NDUFA2 gene are plausible mechanisms of action in dementia protection. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-022-05743-0) contains peer-reviewed but unedited supplementary material.. |
format | Online Article Text |
id | pubmed-9477943 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-94779432022-09-17 Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study Zheng, Jie Xu, Min Walker, Venexia Yuan, Jinqiu Korologou-Linden, Roxanna Robinson, Jamie Huang, Peiyuan Burgess, Stephen Au Yeung, Shiu Lun Luo, Shan Holmes, Michael V. Davey Smith, George Ning, Guang Wang, Weiqing Gaunt, Tom R. Bi, Yufang Diabetologia Article AIMS/HYPOTHESIS: Metformin use has been associated with reduced incidence of dementia in diabetic individuals in observational studies. However, the causality between the two in the general population is unclear. This study uses Mendelian randomisation (MR) to investigate the causal effect of metformin targets on Alzheimer’s disease and potential causal mechanisms in the brain linking the two. METHODS: Genetic proxies for the effects of metformin drug targets were identified as variants in the gene for the corresponding target that associated with HbA(1c) level (N=344,182) and expression level of the corresponding gene (N≤31,684). The cognitive outcomes were derived from genome-wide association studies comprising 527,138 middle-aged Europeans, including 71,880 with Alzheimer’s disease or Alzheimer’s disease-by-proxy. MR estimates representing lifelong metformin use on Alzheimer’s disease and cognitive function in the general population were generated. Effect of expression level of 22 metformin-related genes in brain cortex (N=6601 donors) on Alzheimer’s disease was further estimated. RESULTS: Genetically proxied metformin use, equivalent to a 6.75 mmol/mol (1.09%) reduction on HbA(1c), was associated with 4% lower odds of Alzheimer’s disease (OR 0.96 [95% CI 0.95, 0.98], p=1.06×10(−4)) in non-diabetic individuals. One metformin target, mitochondrial complex 1 (MCI), showed a robust effect on Alzheimer’s disease (OR 0.88, p=4.73×10(−4)) that was independent of AMP-activated protein kinase. MR of expression in brain cortex tissue showed that decreased MCI-related gene (NDUFA2) expression was associated with lower Alzheimer’s disease risk (OR 0.95, p=4.64×10(−4)) and favourable cognitive function. CONCLUSIONS/INTERPRETATION: Metformin use may cause reduced Alzheimer’s disease risk in the general population. Mitochondrial function and the NDUFA2 gene are plausible mechanisms of action in dementia protection. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version of this article (10.1007/s00125-022-05743-0) contains peer-reviewed but unedited supplementary material.. Springer Berlin Heidelberg 2022-07-29 2022 /pmc/articles/PMC9477943/ /pubmed/35902387 http://dx.doi.org/10.1007/s00125-022-05743-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Zheng, Jie Xu, Min Walker, Venexia Yuan, Jinqiu Korologou-Linden, Roxanna Robinson, Jamie Huang, Peiyuan Burgess, Stephen Au Yeung, Shiu Lun Luo, Shan Holmes, Michael V. Davey Smith, George Ning, Guang Wang, Weiqing Gaunt, Tom R. Bi, Yufang Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study |
title | Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study |
title_full | Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study |
title_fullStr | Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study |
title_full_unstemmed | Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study |
title_short | Evaluating the efficacy and mechanism of metformin targets on reducing Alzheimer’s disease risk in the general population: a Mendelian randomisation study |
title_sort | evaluating the efficacy and mechanism of metformin targets on reducing alzheimer’s disease risk in the general population: a mendelian randomisation study |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9477943/ https://www.ncbi.nlm.nih.gov/pubmed/35902387 http://dx.doi.org/10.1007/s00125-022-05743-0 |
work_keys_str_mv | AT zhengjie evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT xumin evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT walkervenexia evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT yuanjinqiu evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT korologoulindenroxanna evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT robinsonjamie evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT huangpeiyuan evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT burgessstephen evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT auyeungshiulun evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT luoshan evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT holmesmichaelv evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT daveysmithgeorge evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT ningguang evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT wangweiqing evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT gaunttomr evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy AT biyufang evaluatingtheefficacyandmechanismofmetformintargetsonreducingalzheimersdiseaseriskinthegeneralpopulationamendelianrandomisationstudy |